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Abstract
Inflammatory bowel diseases are characterised by 
inflammation that compromises the integrity of the 
epithelial barrier. The intestinal epithelium is not only 
a static barrier but has evolved complex mechanisms 
to control and regulate bacterial interactions with 
the mucosal surface. Apical tight junction proteins 
are critical in the maintenance of epithelial barrier 
function and control of paracellular permeability. 
The characterisation of alterations in tight junction 
proteins as key players in epithelial barrier function 
in inflammatory bowel diseases is rapidly enhancing 
our understanding of critical mechanisms in dis-
ease pathogenesis as well as novel therapeutic 
opportunities. Here we give an overview of recent 
literature focusing on the role of tight junction proteins, 
in particular claudins, in inflammatory bowel diseases 
and inflammatory bowel disease associated colorectal 
cancer.
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Core tip: Epithelial barrier function is compromised 
in inflammatory bowel diseases (IBD). Apical tight 
junction proteins, in particular claudins, are key players 
in epithelial barrier function. However, there is little 
consensus regarding the expression of most claudin 
isoforms in these conditions or whether these findings 
are primary or secondary to disease pathogenesis. 
Knowledge of tight junction protein expression and 
function in IBD and IBD associated colorectal cancer 
will enhance our understanding of critical mechanisms 
in disease pathogenesis as well as novel therapeutic 
opportunities.
Landy J, Ronde E, English N, Clark SK, Hart AL, Knight SC, 
Ciclitira PJ, Al-Hassi HO. Tight junctions in inflammatory bowel 
diseases and inflammatory bowel disease associated colorectal 
cancer. World J Gastroenterol 2016; 22(11): 3117-3126  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v22/i11/3117.
htm  DOI: http://dx.doi.org/10.3748/wjg.v22.i11.3117
INTRODUCTION
A number of routes exist for passage across the 
epithelial barrier between the internal and external 
environment. The intercellular spaces between 
adjacent cells, linked together by junctional complexes, 
are critical in regulating the mucosal barrier. Ions 
and solutes pass transcellulary utilising channels, 
carriers and transporting ATPases[1]. The paracellular 
pathway also regulates permeability to water, ions 
and low molecular weight molecules (< 600 kDa). 
The differences in paracellular permeability between 
different epithelia such as the proximal or distal 
nephron, has led to the concept of “leaky” or “tight” 
epithelia. In disease states, epithelia may become 
more “tight” or more “leaky” such as is seen in 
inflammatory  bowel diseases[1]. 
The tight junctions (TJs) form the apical most 
unit, defining the boundary between the apical and 
basolateral membranes and are predominantly the 
rate-limiting factor in paracellular passage[2]. The 
tight junction is built up by both transmembrane 
proteins such as occludin, tricellulin, different claudins 
and junctional adhesion molecules (JAMs), as well 
as peripheral membrane proteins such as zona 
occludens (ZO)-1,-2,-3 and cingulin. They are linked 
to the cytoskeleton of the cell by F-actin and myosin 
Ⅱ[3,4]. These ZO proteins have three PDZ domains 
that mediate binding to other transmembrane tight 
junction proteins such as claudins in a dynamic energy 
dependent manner[5]. They are also the direct targets 
and effectors of different signalling pathways (such 
as the myosin light chain kinase) thereby altering the 
assembly, maintenance, and barrier function of the TJ 
complex[6].
The expression of different TJs in the gut varies 
according to localization (e.g., villus vs crypt, small 
bowel vs colon), cell membrane localization (e.g., 
apical, lateral or basolateral) and the gut’s functional 
properties at the site[4,7,8]. For example, claudin 
2 is expressed at the apical pole throughout the 
crypt-villus axis in the jejunum whilst in the colon 
expression is restricted to the crypts, whereas claudin 
4 expression is throughout the crypt-villus axis in the 
small and large intestine. The segmental distribution 
of claudin expression may relate to cell differentiation, 
carbohydrate metabolism and transcription factors 
such as HNF1α, Cdx2 and GATA-4[9]. 
In health, the apical TJs construct a dynamic 
intestinal barrier that regulates the paracellular uptake 
of water, nutrients and electrolytes[3,5]. TJs may be size 
and/or charge selective and prevent contact between 
the proteins of the two cell poles: the basolateral and 
apical cell membranes[10]. While many tight junction 
proteins have properties of increased barrier formation, 
others form size and/or charge selective channels 
or pores[1]. Adherens junctions and desmosomes 
are mostly involved in communication between 
neighbouring epithelial cells[4,10,11]. TJ dysfunction can 
lead to the disruption of the intestinal barrier integrity. 
Changes in pH, osmotic load or cytoskeleton function 
all affect the barrier function of TJs[12].
There are 27 different claudin isoforms that 
modulate the paracellular movement of ions based on 
charge and size[13]. Claudin 1 and claudin 2 are able 
to initiate the formation of TJ strands on fibroblasts 
lacking TJs, suggesting that they are the major 
components of TJ strands[14]. Claudin 2 controls the 
movement of monovalent cations such as Na+ to 
the interstitium and reduces the paracellular trans-
epithelial resistance as well as enhances trans-
epithelial water flux[15,16] in contrast to other claudins 
(like 1, 3, 4, 5, 8) that tighten the epithelium[17-23]. 
Claudin 2 also directly decreases the barrier function of 
Claudin 1 and Claudin 4 strands[13]. Therefore the ratio 
of different claudins in the TJ determines its functional 
property as either leaky or tight. This review will focus 
on the role of key TJPs (Table 1) in the pathogenesis of 
IBD and IBD associated colorectal cancer (CRC). 
EPITHELIAL BARRIER FUNCTION IN 
INFLAMMATORY BOWEL DISEASES
Inflammatory bowel diseases (IBD) share a 
multifactorial aetiology of genetic susceptibility, 
environmental factors and immune dysregulation[24]. 
These diseases are characterized by intestinal 
inflammation that compromises the integrity of the 
epithelial barrier leading to increased permeability 
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and infiltration of pathogens[25]. Both Crohn’s disease 
(CD) and ulcerative colitis (UC) share common fea-
tures such as epithelial breaks, a reduction in tight 
junction strands, and glandular atrophy[11,26,27]. Patients 
with clinically active CD have increased intestinal 
permeability[28-30]. Barrier dysfunction is likely to be 
caused by epithelial damage including apoptosis, 
erosion and ulceration that are characteristic of gut 
inflammation. Inflammatory cytokines associated with 
gut inflammation alter epithelial permeability through 
their effects on the junctional complexes[31-33]. 
However, impaired barrier function is also evident 
in quiescent IBD and even in first degree relatives of 
patients with CD[34,35]. Genetic studies have identified 
new UC susceptibility loci pertaining to defects of the 
epithelial barrier[36,37]. Barrier properties of ileoanal 
pouch mucosa in both pouchitis and in ileoanal pouches 
where backwash ileitis was present prior to restorative 
proctocolectomy for UC are reduced[38-40] and increased 
bacterial translocation has been reported in pouches 
functioning for longer than 12 mo[41]. Dysregulation 
of the epithelial barrier with changes in paracellular 
permeability due to altered cell to cell junctions is likely 
to be significantly more selective and may be a critical 
primary factor in the pathogenesis of IBD.
ULCERATIVE COLITIS
Gitter et al[42] identified that in the sigmoid colon 
of patients with early UC where the epithelium 
looks intact, there are in fact already leaks from 
apoptotic foci. Furthermore, the higher the degree of 
inflammation observed, the higher the conductance of 
the epithelium measured[42]. A study using epithelial 
resistance as a measure of barrier function in samples 
from UC patients with inflamed sigmoid colon[43] 
demonstrated an 80% reduction in epithelial resistance 
and a decrease in epithelial (not crypt) TJ depth in 
inflamed samples. 
Several studies have focused on expression of 
claudins in UC patients[43-45]. demonstrating higher 
expression of claudin 2 in colonic samples from 
patients with UC. Additionally, the increases in “pore-
forming” claudin 2 correlate with disease severity on 
both protein and transcriptional levels. Reductions 
in other “tightening” tight junctions also occur 
concomitantly. Reduced staining intensity for claudin 
3, 4 and 7 have been shown both on the surface 
epithelium as well as mislocation of claudin 4 extra-
junctionally in UC patients[44,45]. 
In contrast, Poritz et al[46] found an increase in 
claudin 1:occludin ratios in colonic samples from 
UC patients compared with healthy controls and CD 
samples by Western blot analysis. This change in ratio 
was the result of both an increase in claudin 1 and a 
decrease in occludin. Disease severity, measured by 
the degree of inflammation, was directly proportional 
to the alterations seen in TJ structure in UC. In another 
study, claudin 1 was demonstrated to be upregulated 
in the colon of UC patients compared to healthy 
controls, but did not correlate to disease severity[47]. 
In sigmoid samples of active UC patients, a trend 
toward upregulation of claudin 12 (another “tightening” 
claudin) was observed[48]. Claudin 18 expression 
was found to be elevated in UC patients compared 
with controls, but did not correlate with severity of 
inflammation postulating a primary defect in barrier 
function[47].
CROHN’S DISEASE
In CD, intestinal permeability is considered a predictive 
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Table 1  Tight junctions of interest in inflammatory bowel diseases
TJ protein Function Expression in CD Expression in UC Expression
in pouchitis
Claudin 1 Tightens the epithelium[17,23] able to initiate formation of TJ 
strands[14]
Active: ↑[46,65] ↔[50] Active: ↑[65], ↓[40]
Inactive: ↔[65] ↔[45]
Inactive: ↔[65]
Claudin 2 Important pore-forming TJ protein[15,16,23], able to initiate 
formation of TJ strands[14], decreases barrier function of 
CLDN1 and CLDN4[13]
↑[44,50,65,101] ↑↑[44,50,65,101] ↑[40]
Claudin 4 Tightens the epithelium, decreases paracellular conductance 
through decrease in sodium permeability[19]
↓[44] Active: ↓[44,45] ↔[40]
Active inflammation: ↑[65] Active Inflammation: ↑[65]
↔[50]
Claudin 5 Tightens the epithelium[20] ↓[50] ↔[40]
Claudin 8 Tightens the epithelium[21] ↓[50]
Claudin 12 Tightens the epithelium ↑[48]
Claudin 18 Uncertain function ↑[47]
Occludin Binds ZO-1, regulates paracellular 
permeability, function in cellular 
adhesion[102]
↓[46,50,52] ↓[52] ↔[40]
↔[65] ↔[65]
ZO-1 Mediates protein-protein interactions, 
link to actin cytoskeleton: “anchoring” 
protein[4,103]
↓[68] ↔[64] (Mees et al: “in 
patients with a history of 
UC”)
↓[54] (chronic 
pouchitis)
TJ: Tight junction; ZO-1: Zona occludens-1; CD: Crohn’s disease; UC: Ulcerative colitis.
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1B). Analysis of claudin expression from pouch 
biopsies before ileal pouch anal anastomosis (IPAA), 
during pouchitis and at a time point over a year 
after ileostomy closure demonstrated an elevation 
in claudin 2 levels in acute pouchitis[40]. We also 
recently demonstrated altered expression of TJP 
in the ileal pouch of patients with UC. In particular 
increased expression of claudin 2 occurred early 
following ileostomy closure, prior to the development 
of histological inflammation. Claudin 2 was also 
elevated in UC patients without pouchitis compared 
with FAP patients and in acute, but not chronic 
pouchitis samples whilst epithelial expression of ZO-1 
and claudin 1 were reduced in patients with chronic 
pouchitis. These findings suggest that increased 
claudin 2 expression may be an early event in the 
development of inflammation[54].
TIGHT JUNCTIONS AND IBD 
ASSOCIATED COLORECTAL CANCER
Passage of luminal antigens or metabolites through 
diminished epithelial barrier is known to promote 
chronic inflammation and CRC[55-57]. In general, claudins 
are associated with different types of neoplasms, 
including breast, prostate, ovarian, pancreatic, gastric 
and colorectal carcinoma[58,59]. They may also be 
involved in the progression to metastasis, and provide 
unfavourable signalling pathways between the extra- 
and intracellular milieu[60-63]. 
Mees et al[64] investigated the expression of both 
adherens, and TJ proteins in patients with CRC with 
a history of UC. Claudins 1, 3, 4 and β-catenin were 
upregulated in CRC tissue compared with normal 
controls or intraepithelial neoplasia, whilst the ex-
pression of claudin 2, ZO-1 and occludin did not vary 
significantly between samples. Other studies have 
demonstrated elevated claudin 1 and claudin 2 levels 
in IBD-associated carcinoma[59,65,66]. Kinugasa et al[66] 
demonstrated increased staining for claudin 1 in both 
high-grade dysplasia and UC-associated CRC when 
factor for disease susceptibility and relapse[34,49]. 
Changes in tight junctions and epithelial apoptosis 
might dominate in causing barrier dysfunction[50]. Marin 
et al[51] studied 10 patients with CD. The epithelial 
cells of the terminal ileum from these patients 
demonstrated tight junction disorganisation which was 
present in minimally inflamed areas although more 
pronounced in cobblestone areas. 
In samples from the sigmoid colon in active CD, 
the expression of claudins 5, 8 and 3 were decreased, 
whereas claudin 2 expression was moderately 
increased[50]. Kucharzik et al[52] demonstrated similar 
changes in tight junction expression in both UC and 
CD with global down-regulation of occludin. This 
finding was present both in active and quiescent UC 
whilst only in active CD. Das et al[53] showed claudin 2 
to be strongly expressed in the ileum of approximately 
50% of quiescent as well as active CD. Moreover, the 
distribution of claudin 2 expression was altered in 
colonic biopsies from CD patients and associated with 
disrupted tight junctions. Others have found no change 
in ileal expression of claudin 2 in CD, whilst in the 
sigmoid colon of CD patients, claudin 2 was found to 
be significantly down regulated compared to controls. 
However, claudin 12 was found to be increased in the 
ileum of CD patients[48].
POUCHITIS
Barrier properties of ileoanal pouch mucosa in 
pouchitis and in non-inflamed pouches are reduced[38] 
with increased bacterial translocation in long lasting 
pouches[41]. Merrett et al[39] showed an increase in 
pouch permeability in patients with pouchitis compared 
with those with a normally functioning pouch. Electron 
micrography of mucosal epithelium from non-
inflamed UC pouch (Figure 1A) and pouchitis suggests 
membranes between cells are more loosely arranged 
with increased intercellular distance and perijunctional 
cytoskeleton condensation[54]. In addition, dendritic 
cells appear to penetrate the epithelial cell layer 
more frequently (personal communication) (Figure 
Figure 1  Electron microscopy of pouch epithelium tight junction complex in non-inflamed pouch (A) and electron micrograph demonstrating dendritic cell 
penetrating between two epithelial cells in pouchitis (B). Bar = 0.1 μm. Solid arrow: Dendritic cell; Dashed arrow: Tight junction complex between epithelial cell 
and dendritic cell.
A B
Desmosomes
Tight Junction Complex
Cell 1
Cell 2
0.1 μm
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compared with normal or UC colonic samples. 
In the study of Weber et al[65], the expression of 
claudin 1, 2, 4 and occludin were evaluated in IBD 
patients, IBD-associated dysplasia, acute self-limited 
colitis (ASLC) and sporadic adenomas. During active 
inflammation, claudin 1 expression was upregulated 
in both UC and CD patients and localization of claudin 
1 was not limited to the TJ, but was expressed on 
the lateral membrane. Claudin 2 expression was the 
richest in the TJ region and the apical cytoplasm. In 
an identical manner to claudin 1, the expression of 
claudin 2 correlated with the degree of inflammation 
in both UC and CD, but not in ASLC[65]. Claudin 1 and 
claudin 2 levels were also increased in IBD-associated 
dysplasia and sporadic adenomas in comparison to 
non-dysplastic IBD. However, occludin expression 
and localization in both active and inactive IBD and in 
adenomas or carcinomas was no different compared 
with controls. The changes in TJ expression in IBD 
associated dysplasia may represent the severity and 
longevity of histological inflammation, a known risk 
factor for neoplastic progression in IBD[67]. 
CHICKEN OR EGG?
It is not clear whether the changes observed in tight 
junctions in IBD are causal, leading to abnormal 
epithelial barrier integrity and the aberrant immune 
responses, or whether the inflammation itself causes 
the alterations in tight junction expression and 
distribution. 
Inflammatory cytokines and tight junction regulation
Heller et al[31] demonstrated a significant upregulation 
of IL-13 in patients with UC compared to CD patients 
and non-inflammatory controls. Following the upre-
gulation of IL-13, there was a decrease in trans-
epithelial resistance and an increase in epithelial cell 
apoptosis and conductance. Furthermore, IL-13 caused 
an upregulation of the claudin 2 gene, thus elevating 
claudin 2 protein production threefold. IL-13 did not 
have a significant effect on the expression of occludin, 
claudin 1 and claudin 4. 
In CD, interferon gamma (IFN-γ) contributes to 
impairment of epithelial barrier function through 
disrupting tight junction complexes by causing 
decreased expression and increased internalization of 
occludin and ZO-1[68]. The effects of IFN-γ on barrier 
function may be mediated through 5’ adenosine 
monophosphate-activated protein kinase (AMPK). 
AMPK is key in sensing the cell’s energy levels, which 
decrease during inflammation and subsequently 
increase the demand for AMPK. Scharl et al[68] showed 
that inhibiting AMPK not only reverses its effect on 
TJs but also its negative effect on trans epithelial 
resistance. Watson et al[69] also showed in T84 
cells (model intestinal epithelial cell line) that IFN-γ 
increased intestinal permeability to large molecules 
such as E. coli-derived lipopolysaccharide. Effects 
were exerted presumably by decreasing expression of 
occludin and increasing the expression of claudin 1 but 
expression of claudin 2 or 3 were not affected[69]. 
TNF-α can also affect tight junctions and decrease 
epithelial barrier function by increasing Myosin Light 
Chain Kinase (MLCK) phosphorylation. Inhibition of 
MLCK in TNF-α treated epithelial monolayers can 
acutely restore barrier function[32]. Furthermore, MLCK-
activation promotes IL-13 expression and claudin 
2 synthesis[70]. TNF-α induced MLCK expression 
may therefore be a critical mechanism for barrier 
dysfunction in UC and CD. Ileal MLCK expression 
is increased in ileal biopsies from patients with CD 
compared with controls and increased MLCK correlates 
with disease activity[71]. 
Animal models of epithelial permeability and 
inflammation
A recent study of transgenic mice expressing activated 
MLCK showed increased paracellular permeability 
without histological inflammation. Further analysis 
however, found an increase in the absolute numbers 
of lamina propria CD4+ lymphocytes and a significant 
redistribution of CD11c+ dendritic cells to the 
superficial lamina propria as well as polarisation to a 
Th1 cytokine profile[72]. Despite increased epithelial 
permeability these mice did not develop intestinal 
inflammation. However, when crossed with mice that 
develop spontaneous inflammation an accelerated and 
exaggerated inflammatory response was seen. This 
mouse model therefore suggests that barrier loss may 
not initiate inflammation but accelerate inflammatory 
responses.
Other studies suggest that tight junction abnor-
malities and epithelial permeability may precede the 
increase of inflammatory cytokines. Interleukin-10 
(IL-10) blocks IFN-γ induced epithelial permeability 
and IL-10 knockout mice have increased permeability 
and spontaneously develop chronic intestinal inflam-
mation[33]. Inhibition of the zonulin receptor (a key 
receptor in tight junction binding regulation) in 
IL-10 knockout mice reduced intestinal permeability 
and attenuated the spontaneous development of 
colitis[33]. However, increased intestinal permeability 
in IL-10 knockout mice not only preceded the onset 
of inflammation but also occurred significantly earlier 
than any differences in IFN-γ or TNF-α. 
A recent study of intestine-specific claudin 7 
knockout mice[73] demonstrated increased neutrophil 
infiltration into the lamina propria and increased mRNA 
expression of inflammatory cytokines without altered 
epithelial integrity. Further investigation showed 
increased epithelial permeability and paracellular 
absorption of small molecules and increased absorption 
of a bacterial derived neutrophil chemoattractant in 
the claudin 7 knockouts. Treatment with antibiotics 
or exogenous administration of the soluble bacterial 
derived chemoattractant, abolished and initiated 
the onset of inflammation respectively. This model 
Landy J et al . Tight junctions in IBD
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suggests that the loss of claudin 7 enabled increased 
absorption of soluble bacterial products leading to the 
development of colonic inflammation. 
Ileoanal pouch as a human model for inflammatory 
bowel disease
Unlike UC and CD, the ileal pouch offers a unique 
opportunity to study the development of inflammation 
before disease onset. In patients with UC, increased 
epithelial expression of the “pore-forming” tight 
junction claudin 2 was an early event after ileostomy 
closure and preceded increased IL-6 levels, as well as 
increased TLR4 and CD40 activation marker expression 
in patients with mucosal inflammation of the pouch at 
twelve months following ileostomy closure[54].
THERAPEUTIC OPPORTUNITY IN 
INFLAMMATORY BOWEL DISEASES
Strategies to manipulate tight junctions and intestinal 
permeability are likely to have an important role in the 
future treatment of inflammatory bowel diseases. 
Anti-TNF therapy and tight junctions
Anti-TNF therapy is effective in the treatment of Crohn’s 
disease, ulcerative colitis and chronic pouchitis[74-76]. 
Barrier function is significantly restored following 
anti-TNF therapy for CD[77,78]. In the study by Zeissig 
et al[78], this was associated with a reduction in 
epithelial apoptosis but no significant changes in 
occludin, claudin 1 or claudin 4. However, other 
claudins including claudin 2 were not assessed. In a 
study of experimental colitis in mice, both etanercept 
and infliximab attenuated inflammation induced 
reductions in ZO-1 and occludin as well as reducing 
the upregulation of claudin 2[79]. More recently, in 
epithelial cell lines adalimumab prevented increased 
phosphorylation of myosin light chain and reversed the 
TNF induced down regulation of claudins 1 and 4[80].
Short chain fatty acids
In the colon, anaerobic bacterial fermentation of 
undigested polysaccharides leads to the production 
of short chain fatty acids, particularly acetic, 
proprionic and butyric acids. Short chain fatty acids, 
in particular butyrate are thought to be the principal 
source of energy for colonocytes and in UC patients 
colonocytes have demonstrated diminished oxidation 
of butyrate[81,82]. In vitro culture demonstrated butyrate 
enhanced claudin 1 transcription and enhanced barrier 
function[83,84]. In colonic epithelial cells treated with 
butyrate claudin 2 was down regulated[85]. Butyrate 
might be postulated to have a role in maintaining 
barrier function via tight junction regulation. 
Novel compounds and probiotics
Novel compounds that alter epithelial barrier function 
may be available from nutritional sources. Several 
plant extracts have been observed to regulate TJ 
expression. Quercetin, a common flavanoid increase 
epithelial resistance in Caco-2 cell monolayers by 
upregulating claudin 4 expression[86]. Berberine, an 
isoquinolone alkaloid, prevented TNF-α induced claudin 
1 disassembly and upregulation of claudin 2 in a cell 
culture model[87]. Polyunsaturated fatty acids can also 
have beneficial effects on the assembly and morphology 
of TJs[88]. Omega-3 and omega 6 polyunsaturated 
fatty acids up-regulate expression of occludin, reduce 
permeability and strengthen the epithelial barrier[89] 
Polyunsaturated fatty acids also reverse the disruptions 
in TJs caused by proinflammatory cytokines in Caco 2 
epithelial cells[90,91] and might play a role in preventing 
the alteration in the epithelial barrier caused by 
inflammation or proinflammatory cytokines that could 
be exploited as a therapeutic target in the treatment of 
gut inflammation.
Much attention has focused on the effects probiotic 
bacteria and their products may have on tight 
junction expression and epithelial barrier function[92]. 
In vitro and animal models have shown Lactobacilli 
to attenuate epithelial permeability in experimental 
colitis and to upregulate tight junction expression of 
ZO-1, occludin and claudin-3[93-95]. VSL#3 (a mixture 
of eight probiotic strains) prevented the reduction 
and redistribution of ZO-1 and claudins -1,-3,-4 
and -5 in a murine model of colitis. Furthermore, 
bacterial products may be a source of novel therapies 
affecting epithelial barrier function. Uncharacterized 
extracellular proteins secreted by B. longum subsp. 
infantis, increased the production of ZO-1 and occludin 
in epithelial cells[96]. Extracellular proteins derived from 
Lactobacillus rhamnosus GG attenuated reduction in 
epithelial resistance in an in vitro model, preventing 
the redistribution of tight junction proteins including 
ZO-1 and occludin in a dose dependent manner[97]. 
Moreover, Salmonella infection increased claudin-2 
expression in epithelial cell lines facilitating its 
invasion. Therefore, blocking claudin-2 as a potential 
therapeutic target to prevent bacterial invasion has 
been suggested[98]. 
Zonulin has been shown to be a key regulator of 
intestinal permeability through modulation of epithelial 
tight junctions[99]. A synthetic peptide inhibitor 
of zonulin known as AT 1001 or Larazotide has 
undergone clinical studies in the treatment of coeliac 
disease[100]. In the IL-10 knockout mouse, AT 1001 
reduced intestinal permeability and attenuated the 
development of spontaneous colitis[33]. Future studies 
are necessary to determine the role these proteins 
may have in modulating tight junctions and epithelial 
barrier function in inflammatory bowel diseases.
CONCLUSION
Dysregulation of TJ proteins is involved and may 
precede the development of IBD. It is probable that 
they also contribute to the development of IBD-
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associated CRC. Recent evidence suggests that a 
dysregulated expression of TJ proteins may precede 
the development of intestinal inflammation. However, 
a number of questions remain unanswered regarding 
the role of TJs in the aetiology of inflammatory bowel 
diseases. Significant differences may exist between 
animal models and human studies regarding TJ 
expression profiles and further human studies are 
necessary to elucidate the role of TJs in IBD aetiology 
or acceleration of aberrant inflammatory responses. 
Claudin 2 appears to be upregulated in UC, CD 
and pouchitis and some studies also suggest elevated 
claudin 2 to be present in quiescent disease. However, 
there is little consensus regarding the up- or down 
regulation of the other claudin isoforms in these 
conditions. This may be explained to some extent 
by methodological differences and heterogeneity of 
patients and sampling with regard to disease activity 
and history. Further evaluation of the patterns of 
expression of claudins in active and inactive IBD 
patients should help to elucidate their contribution to 
disease, but longitudinal studies are also necessary. 
Future studies should evaluate therapeutic approaches 
that manipulate TJs, restoring epithelial barrier 
integrity, for the treatment of active inflammatory 
bowel diseases, maintenance of remission and 
prevention of onset of inflammation in the gut. 
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